Using prandial insulin to achieve glycemic control in type 2 diabetes.
Dailey
George E
GE
Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, CA 92037, USA. dailey.george@scrippshealth.org
D000465:Algorithms; D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D000069450:Liraglutide; D010455:Peptides / Q000008:administration & dosage; D019518:Postprandial Period; D011719:Pyrazines / Q000008:administration & dosage; D012307:Risk Factors; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000008:administration & dosage; D014688:Venoms / Q000008:administration & dosage
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D000069036:Insulin Glargine; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; D000068900:Sitagliptin Phosphate